Ani Pharmaceutic Stock Price, News & Analysis

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced an underwritten public offering of its common stock, subject to market conditions. The company intends to use the net proceeds for Cortrophin commercialization efforts, including sales and marketing, and for general corporate purposes, which may include acquiring or investing in additional businesses and technologies. Guggenheim Securities is acting as the book-running manager. The offering is part of a shelf registration statement with the SEC effective since July 17, 2020.

ANI Pharmaceuticals reported Q3 2021 net revenues of $52.1 million, a slight decrease from $53.0 million in Q3 2020. The company faced a net loss of $4.4 million with a diluted loss per share of ($0.37). Adjusted non-GAAP EBITDA was $16.6 million with adjusted diluted EPS at $1.01. The FDA approved the Purified Cortrophin™ Gel for chronic autoimmune disorders, with a launch planned for Q1 2022. Additionally, the acquisition of Novitium Pharma LLC is set to close in November 2021, and the company launched Nebivolol Tablets from two sites.

ANI Pharmaceuticals announced FDA approval for Cortrophin Gel, a critical treatment for chronic autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. This approval restores much-needed options for patients and physicians in the U.S. market. ANI plans a full-scale launch in early Q1 2022, following a significant investment in manufacturing. The gel offers alternatives for patients intolerant to corticosteroids, marking a pivotal return to a long-standing treatment option first approved in 1954.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced it will release its third quarter 2021 financial results on November 1, 2021, at 8:30 a.m. ET. The call will be hosted by President and CEO Nikhil Lalwani and Senior VP and CFO Stephen P. Carey. Investors can access the live webcast at www.anipharmaceuticals.com, where a replay will also be available. The company focuses on developing, manufacturing, and marketing both branded and generic pharmaceuticals, aiming for sustainable growth through various initiatives in the bio-pharmaceutical sector.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 8:00 a.m. ET. The presentation will be available via a live webcast and archived for 30 days on the Company's website under the Investors section. ANI Pharmaceuticals is dedicated to developing, manufacturing, and marketing quality pharmaceutical products, focusing on sustainable growth through its Purified Cortrophin Gel® franchise and generics business.

ANI Pharmaceuticals has launched its generic version of Bystolic, called Nebivolol Tablets, available in 2.5 mg, 5 mg, 10 mg, and 20 mg dosages. The U.S. market for Bystolic is approximately $1.05 billion. The launch was executed simultaneously from two manufacturing sites, demonstrating ANI's supply chain capabilities. Nebivolol is prescribed for treating hypertension and can be used alone or with other medications. The company emphasizes its commitment to sustainable growth through its generics division and innovative product development.

ANI Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for Purified Cortrophin Gel. This is a significant milestone with a target action date set for October 29, 2021. The company plans to launch this second ACTH-based treatment, which is vital for patients with chronic autoimmune disorders like multiple sclerosis and rheumatoid arthritis. ANI Pharmaceuticals aims to strengthen its market position through this new drug while continuing to enhance its generics business.

ANI Pharmaceuticals reported financial results for Q2 2021, with net revenues at $48.6 million, slightly up from $48.5 million in Q2 2020. The net loss for the quarter was $14.1 million, compared to $12.3 million the previous year. Key highlights include the refiling of the sNDA for Cortrophin® Gel and the ongoing acquisition of Novitium Pharma, expected to close later this year. Despite increased revenues from generic and branded products, operating expenses rose to $64.2 million, impacting profitability. The company held $24.3 million in cash and cash equivalents, with total debt of $205.7 million.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its second quarter 2021 financial results on August 6, 2021. A conference call is scheduled for 8:30 a.m. ET, led by CEO Nikhil Lalwani and CFO Stephen P. Carey. Participants can join via a toll-free number or access the live webcast on the company's website. A replay will be available shortly after the call and for one week. ANI specializes in developing high-quality branded and generic pharmaceuticals, focusing on niche markets like controlled substances and oncology products.